Skip to main content
Talia Barzel Baker
( out of 12 reviews )

Talia Barzel Baker, MD, FACS

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
801-587-4700

University of Utah Hospital

Transplant Center
801-581-2121

University of Utah Hospital

Liver Transplant
801-581-2121
  • Talia Baker, MD, is an internationally renowned, expert and leader with more than 20 years of outstanding achievements in the field of transplantation. She joins the University of Utah as the Chief of the Division of Transplantation and Advanced Hepatobiliary Surgery.

    Dr. Baker comes to us from the University of Chicago, where she served as Professor of Surgery, Director of Transplant Oncology, Director of Living Donor Liver Transplantation, and as Surgical Director of Liver Transplantation. Dr. Baker completed her general surgical residency at the New York-Presbyterian Medical Center, followed by her multi-organ transplant fellowship training at Northwestern University Feinberg School of Medicine, where she remained until her appointment at the University of Chicago.

    Dr. Baker is the Executive Medical Director of the Transplant Service Line, Surgical Director of Liver Transplantation, and Chief of the Division of Transplantation and Advanced Hepatobiliary Surgery at the University of Utah. Dr. Baker brings extensive leadership experience and as Division Chief, she will work collaboratively with the surgical transplant service line team and affiliates, including transplant services at Primary Children’s Hospital and Intermountain Medical Center, and Hepatobiliary Oncology at Huntsman Cancer Institute and Hospital.

    For more information on University of Utah Health's Transplant Services, please visit our website: healthcare.utah.edu/transplant

    Patient Rating

    4.5 /5
    ( out of 12 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 20, 2023
    UH HOSPITALS AND CLINICS

    I don't think I saw her long enough to have an opinion honestly.

    August 05, 2023
    HUNTSMAN CANCER CENTER

    Dr. Baker is the best. She has been so wonderful from the first time we met her. She helped us through the testing for a liver transplant and was instrumental in helping us get a liver. We think she is great.

    May 19, 2023
    HUNTSMAN CANCER CENTER

    Dr. Baker is the best! She is a skilled surgeon beyond compare. Her compassion and ability are so appreciated by me. I hope anyone needing any kind of liver surgery will come to her.

    February 15, 2023
    HUNTSMAN CANCER CENTER

    Two thumbs up

    February 09, 2023
    HUNTSMAN CANCER CENTER

    Very professional and informative and gave me and my family great confidence in the cancer treatment she had planned. Absolutly the BEST...Outstanding staff also

    December 14, 2022
    HUNTSMAN CANCER CENTER

    Dr. Baker is a excellent doctor/surgeon. She is a life saver!

  • Talia Baker, MD, is an internationally renowned, expert and leader with more than 20 years of outstanding achievements in the field of transplantation. She joins the University of Utah as the Chief of the Division of Transplantation and Advanced Hepatobiliary Surgery.

    Dr. Baker comes to us from the University of Chicago, where she served as Professor of Surgery, Director of Transplant Oncology, Director of Living Donor Liver Transplantation, and as Surgical Director of Liver Transplantation. Dr. Baker completed her general surgical residency at the New York-Presbyterian Medical Center, followed by her multi-organ transplant fellowship training at Northwestern University Feinberg School of Medicine, where she remained until her appointment at the University of Chicago.

    Dr. Baker is the Executive Medical Director of the Transplant Service Line, Surgical Director of Liver Transplantation, and Chief of the Division of Transplantation and Advanced Hepatobiliary Surgery at the University of Utah. Dr. Baker brings extensive leadership experience and as Division Chief, she will work collaboratively with the surgical transplant service line team and affiliates, including transplant services at Primary Children’s Hospital and Intermountain Medical Center, and Hepatobiliary Oncology at Huntsman Cancer Institute and Hospital.

    For more information on University of Utah Health's Transplant Services, please visit our website: healthcare.utah.edu/transplant

    Board Certification and Academic Information

    Academic Departments Surgery -Primary
    Academic Divisions Transplant & Advanced Hepatobiliary Surgery

    Education history

    Fellowship Multi-Organ Transplant - Northwestern University Feinberg School of Medicine Fellow
    Surgery - New York-Presbyterian Hospital Chief Resident
    Residency General Surgery - New York-Presbyterian Hospital Resident
    Medicine - Tufts University School of Medicine M.D.
    Undergraduate History - Yale University B.A.

    Selected Publications

    Journal Article

    1. Ahmed O, Yu Q, Patel M, Hwang G, Pillai A, Liao CY, Fung J, Baker T (2022). Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol, 34(4), 702-709. (Read full article)
    2. Kim P, Littau M, Baker TB, Abdelsattar Z, Tonelli C, Bunn C, Kulshrestha S, Luchette FA, Scaglione S, Baker MS (2022). The benefit of liver transplant beyond Milan criteria: An analysis using the National Cancer Database. Surgery, 172(6), 1823-1828. (Read full article)
    3. Talwar A, Varghese J, Knight GM, Katariya N, Caicedo JC, Dietch Z, Borja-Cacho D, Ladner D, Christopher D, Baker T, Abecassis M, Mouli S, Desai K, Riaz A, Thornburg B, Salem R (2022). Preoperative portal vein recanalization-transjugular intrahepatic portosystemic shunt for chronic obliterative portal vein thrombosis: Outcomes following liver transplantation. Hepatol Commun, 6(7), 1803-1812. (Read full article)
    4. Perez-Gutierrez A, Siddiqi U, Kim G, Rangrass G, Kacha A, Jeevanandam V, Becker Y, Potter L, Fung J, Baker TB (2022). Combined heart-liver-kidney transplant: The university of Chicago medicine experience. Clin Transplant, 36(4), e14586. (Read full article)
    5. Kim P, Littau M, Baker TB, Abdelsattar Z, Tonelli C, Bunn C, Kulshrestha S, Luchette FA, Baker MS (2021). Intrahepatic cholangiocarcinoma: Is there a role for liver transplantation? Surgery, 171(3), 741-746. (Read full article)
    6. Strauss AT, Boyarsky BJ, Garonzik-Wang JM, Werbel W, Durand CM, Avery RK, Jackson KR, Kernodle AB, Baker T, Snyder J, Segev DL, Massie AB (2020). Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses. Am J Transplant, 21(5), 1838-1847. (Read full article)
    7. Jayant K, Reccia I, Virdis F, Pyda JS, Bachul PJ, di Sabato D, Barth RN, Fung J, Baker T, Witkowski P (2021). COVID-19 in hospitalized liver transplant recipients: An early systematic review and meta-analysis. Clin Transplant, 35(4), e14246. (Read full article)
    8. Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K, Mora RA, Ganger D, Maddur H, Flamm S, Boike J, Moore C, Thornburg B, Alasadi A, Baker T, Borja-Cacho D, Katariya N, Ladner DP, Caicedo JC, Lewandowski RJ, Salem R (2020). Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology, 73(3), 998-1010. (Read full article)
    9. Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T, Dalag L, Han R, Ahmed O (2021). Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol, 94(1119), 20200752. (Read full article)
    10. Boyarsky BJ, Ruck JM, Chiang TP, Werbel WA, Strauss AT, Getsin SN, Jackson KR, Kernodle AB, Van Pilsum Rasmussen SE, Baker TB, Al Ammary F, Durand CM, Avery RK, Massie AB, Segev DL, Garonzik-Wang JM (2020). Evolving Impact of COVID-19 on Transplant Center Practices and Policies in the United States. Clin Transplant, 34(12), e14086. (Read full article)
    11. Soubrane O, Eguchi S, Uemoto S, Kwon CHD, Wakabayashi G, Han HS, Kim KH, Troisi RI, Cherqui D, Rotellar F, Cauchy F, Soyama A, Ogiso S, Choi GS, Takahara T, Cho JY, Cho HD, Vanlander A, Pittau G, Scatton O, Pardo F, Baker T (2020). Minimally Invasive Donor Hepatectomy for Adult Living Donor Liver Transplantation: An International, Multi-Institutional Evaluation of Safety, Efficacy and Early Outcomes. Ann Surg. (Read full article)
    12. Ahmed O, Salaskar AL, Zangan S, Pillai A, Baker T (2020). Transsplenic portal vein recanalization and direct intrahepatic portosystemic shunt placement to optimize liver transplantation. CVIR Endovasc, 3(1), 5. (Read full article)
    13. Gabr A, Abouchaleh N, Ali R, Baker T, Caicedo J, Katariya N, Abecassis M, Riaz A, Lewandowski RJ, Salem R (2018). Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol, 29(11), 1502-1510.e1. (Read full article)
    14. Bodzin AS, Baker TB (2018). Liver Transplantation Today: Where We Are Now and Where We Are Going. Liver Transpl, 24(10), 1470-1475. (Read full article)
    15. Benjamin AJ, Baker TB, Talamonti MS, Bodzin AS, Schneider AB, Winschester DJ, Roggin KK, Bentrem DJ, Suss NR, Baker MS (2018). Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function. Surgery, 163(3), 582-586. (Read full article)
    16. Kallini JR, Gabr A, Ali R, Abouchaleh N, Riaz A, Baker T, Kulik L, Caicedo J, Salem R, Lewandowski RJ (2017). Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience. Cardiovasc Intervent Radiol, 41(2), 231-238. (Read full article)
    17. Baker TB, Zimmerman MA, Goodrich NP, Samstein B, Pomfret EA, Pomposelli JJ, Gillespie BW, Berg CL, Emond JC, Merion RM (2017). Biliary reconstructive techniques and associated anatomic variants in adult living donor liver transplantations: The adult-to-adult living donor liver transplantation cohort study experience. Liver Transpl, 23(12), 1519-1530. (Read full article)
    18. Thornburg B, Desai K, Hickey R, Hohlastos E, Kulik L, Ganger D, Baker T, Abecassis M, Caicedo JC, Ladner D, Fryer J, Riaz A, Lewandowski RJ, Salem R (2017). Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Final Analysis of a 61-Patient Cohort. J Vasc Interv Radiol, 28(12), 1714-1721.e2. (Read full article)
    19. Liu JB, Baker TB, Suss NR, Talamonti MS, Roggin KK, Winchester DJ, Baker MS (2017). Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function. Surgery, 162(5), 1032-1039. (Read full article)
    20. Emond JC, Goodrich NP, Pomposelli JJ, Baker TB, Humar A, Grant DR, Abt P, Friese CE, Fisher RA, Kam I, Sherker AH, Gillespie BW, Merion RM (2017). Hepatic Hemodynamics and Portal Flow Modulation: The A2ALL Experience. Transplantation, 101(10), 2375-2384. (Read full article)
    21. Gabr A, Kallini JR, Gates VL, Hickey R, Kulik L, Desai K, Thornburg B, Marshall K, Salzig K, Williams M, Del Castillo C, Ganger D, Hohlastos E, Baker T, Lewandowski RJ, Salem R (2016). Same-day 90Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging, 43(13), 2353-2359. (Read full article)
    22. Lewandowski RJ, Andreoli JM, Hickey R, Kallini JR, Gabr A, Baker T, Kircher S, Salem R, Kulik L (2016). Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. J Vasc Interv Radiol, 27(9), 1329-1336. (Read full article)
    23. Gordon EJ, Mullee J, Skaro A, Baker T (2016). Live liver donors' information needs: A qualitative study of practical implications for informed consent. Surgery, 160(3), 671-82. (Read full article)
    24. Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, Abecassis M, Fryer J, Salem R, Baker T (2016). (90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol, 114(1), 99-105. (Read full article)
    25. Pomposelli JJ, Goodrich NP, Emond JC, Humar A, Baker TB, Grant DR, Fisher RA, Roberts JP, Olthoff KM, Gillespie BW, Merion RM (2016). Patterns of Early Allograft Dysfunction in Adult Live Donor Liver Transplantation: The A2ALL Experience. Transplantation, 100(7), 1490-9. (Read full article)
    26. Thornburg B, Desai K, Hickey R, Kulik L, Ganger D, Baker T, Abecassis M, Lewandowski RJ, Salem R (2016). Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Technical Considerations. Tech Vasc Interv Radiol, 19(1), 52-60. (Read full article)
    27. Samstein B, Smith AR, Freise CE, Zimmerman MA, Baker T, Olthoff KM, Fisher RA, Merion RM (2015). Complications and Their Resolution in Recipients of Deceased and Living Donor Liver Transplants: Findings From the A2ALL Cohort Study. Am J Transplant, 16(2), 594-602. (Read full article)
    28. Wolf JH, Holmes MV, Fouraschen S, Keating BJ, Baker T, Emond J, Rader DJ, Shaked A, Olthoff KM (2015). Serum lipid expression correlates with function and regeneration following living donor liver transplantation. Liver Transpl, 22(1), 103-10. (Read full article)
    29. Salem R, Vouche M, Baker T, Herrero JI, Caicedo JC, Fryer J, Hickey R, Habib A, Abecassis M, Koller F, Vogelzang R, Desai K, Thornburg B, Hohlastos E, Resnick S, Lewandowski RJ, Sato K, Ryu RK, Ganger D, Kulik L (2015). Pretransplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein Thrombosis. Transplantation, 99(11), 2347-55. (Read full article)
    30. Gordon EJ, Mullee J, Butt Z, Kang J, Baker T (2015). Optimizing informed consent in living liver donors: Evaluation of a comprehension assessment tool. Liver Transpl, 21(10), 1270-9. (Read full article)
    31. Gordon EJ, Rodde J, Skaro A, Baker T (2015). Informed consent for live liver donors: A qualitative, prospective study. J Hepatol, 63(4), 838-47. (Read full article)
    32. Olthoff KM, Smith AR, Abecassis M, Baker T, Emond JC, Berg CL, Beil CA, Burton JR Jr, Fisher RA, Freise CE, Gillespie BW, Grant DR, Humar A, Kam I, Merion RM, Pomfret EA, Samstein B, Shaked A (2015). Defining long-term outcomes with living donor liver transplantation in North America. Ann Surg, 262(3), 465-75; discussion 473-5. (Read full article)
    33. Chang Y, Gallon L, Shetty K, Chang Y, Jay C, Levitsky J, Ho B, Baker T, Ladner D, Friedewald J, Abecassis M, Hazen G, Skaro AI (2014). Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies. Transplantation, 99(2), 424-30. (Read full article)
    34. Emond JC, Fisher RA, Everson G, Samstein B, Pomposelli JJ, Zhao B, Forney S, Olthoff KM, Baker TB, Gillespie BW, Merion RM (2014). Changes in liver and spleen volumes after living liver donation: a report from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Liver Transpl, 21(2), 151-61. (Read full article)
    35. Olthoff KM, Emond JC, Shearon TH, Everson G, Baker TB, Fisher RA, Freise CE, Gillespie BW, Everhart JE (2014). Liver regeneration after living donor transplantation: adult-to-adult living donor liver transplantation cohort study. Liver Transpl, 21(1), 79-88. (Read full article)
    36. Levitsky J, Baker TB, Jie C, Ahya S, Levin M, Friedewald J, Al-Saden P, Salomon DR, Abecassis MM (2014). Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation. Hepatology, 60(6), 2017-26. (Read full article)
    37. McElroy LM, Daud A, Davis AE, Lapin B, Baker T, Abecassis MM, Levitsky J, Holl JL, Ladner DP (2014). A meta-analysis of complications following deceased donor liver transplant. Am J Surg, 208(4), 605-18. (Read full article)
    38. Chang Y, Gallon L, Jay C, Shetty K, Ho B, Levitsky J, Baker T, Ladner D, Friedewald J, Abecassis M, Hazen G, Skaro AI (2013). Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl, 20(9), 1034-44. (Read full article)
    39. Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, Habib A, Karp J, Al-Saden P, Lacouture M, Cotliar J, Abecassis M, Baker T, Salem R (2014). Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol, 61(2), 309-17. (Read full article)
    40. Memon K, Kulik LM, Lewandowski RJ, Wang E, Wang J, Ryu RK, Hickey R, Vouche M, Baker T, Ganger D, Gates VL, Habib A, Mulcahy MF, Salem R (2014). Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol, 25(7), 1056-66. (Read full article)
    41. Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, Mulcahy M, Baker T, Abecassis M, Sato KT, Caicedo JC, Fryer J, Hickey R, Hohlastos E, Lewandowski RJ, Salem R (2014). Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology, 60(1), 192-201. (Read full article)
    42. Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T, Mulcahy M, Nayar R, Lewandowski RJ, Salem R (2013). Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology, 58(5), 1655-66. (Read full article)
    43. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, Gaba RC, Mulcahy MF, Baker T, Sato K, Hickey R, Ganger D, Riaz A, Fryer J, Caicedo JC, Abecassis M, Kulik L, Salem R (2013). Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol, 59(5), 1029-36. (Read full article)
    44. Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB 3rd, Mulcahy MF, Kulik L, Lewandowski R (2013). Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol, 11(10), 1358-1365.e1. (Read full article)
    45. Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, Ryu RK, Salem R, Lewandowski RJ (2013). Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol, 24(8), 1227-34. (Read full article)
    46. Zimmerman MA, Baker T, Goodrich NP, Freise C, Hong JC, Kumer S, Abt P, Cotterell AH, Samstein B, Everhart JE, Merion RM (2012). Development, management, and resolution of biliary complications after living and deceased donor liver transplantation: a report from the adult-to-adult living donor liver transplantation cohort study consortium. Liver Transpl, 19(3), 259-67. (Read full article)
    47. Leventhal JR, Kocak B, Salvalaggio PR, Koffron AJ, Baker TB, Kaufman DB, Fryer JP, Abecassis MM, Stuart FP (2004). Laparoscopic donor nephrectomy 1997 to 2003: lessons learned with 500 cases at a single institution. Surgery, 136(4), 881-90. (Read full article)
    48. Heyer EJ, Lee KS, Manspeizer HE, Mongero L, Spanier TB, Caliste X, Esrig B, Smith C (2002). Heparin-bonded cardiopulmonary bypass circuits reduce cognitive dysfunction. J Cardiothorac Vasc Anesth, 16(1), 37-42. (Read full article)
    49. Mongero LB, Beck JR, Manspeizer HE, Heyer EJ, Lee K, Spanier TA, Smith CR (2001). Cardiac surgical patients exposed to heparin-bonded circuits develop less postoperative cerebral dysfunction than patients exposed to non-heparin-bonded circuits. Perfusion, 16(2), 107-11. (Read full article)
    50. Spanier T, Tector K, Schwartz G, Chen J, Oz M, Beck J, Mongero L (2000). Endotoxin in pooled pericardial blood contributes to the systemic inflammatory response during cardiac surgery. Perfusion, 15(5), 427-31. (Read full article)
    51. Williams MR, DAmbra AB, Beck JR, Spanier TB, Morales DL, Helman DN, Oz MC (2000). A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg, 70(3), 873-7. (Read full article)
    52. Chen JM, Cullinane S, Spanier TB, Artrip JH, John R, Edwards NM, Oz MC, Landry DW (1999). Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation, 100(19 Suppl), II244-6. (Read full article)
    53. Spanier TB, Chen JM, Oz MC, Stern DM, Rose EA, Schmidt AM (1999). Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant response. J Thorac Cardiovasc Surg, 118(3), 404-13. (Read full article)
    54. Spanier TB, Chen JM, Mancini DM, Smith CR, Edwards NM (1999). Cardiac transplantation in a patient with protein S deficiency. Ann Thorac Surg, 68(3), 1078-80. (Read full article)
    55. Ankersmit HJ, Tugulea S, Spanier T, Weinberg AD, Artrip JH, Burke EM, Flannery M, Mancini D, Rose EA, Edwards NM, Oz MC, Itescu S (1999). Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet, 354(9178), 550-5. (Read full article)
    56. Sun BC, Catanese KA, Spanier TB, Flannery MR, Gardocki MT, Marcus LS, Levin HR, Rose EA, Oz MC (1999). 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann Thorac Surg, 68(2), 688-94. (Read full article)
    57. Smith CR, Spanier TB (1999). Aprotinin in deep hypothermic circulatory arrest. Ann Thorac Surg, 68(1), 278-86. (Read full article)
    58. Chen JM, DeRose JJ, Slater JP, Spanier TB, Dewey TM, Catanese KA, Flannery MA, Oz MC (1999). Improved survival rates support left ventricular assist device implantation early after myocardial infarction. J Am Coll Cardiol, 33(7), 1903-8. (Read full article)
    59. Chen JM, Spanier TB, Gonzalez JJ, Marelli D, Flannery MA, Tector KA, Cullinane S, Oz MC (1999). Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance. J Heart Lung Transplant, 18(4), 351-7. (Read full article)
    60. Spanier TB, Chen JM, Oz MC, Edwards NM, Kisiel W, Stern DM, Rose EA, Schmidt AM (1998). Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg, 116(5), 860-9. (Read full article)
    61. Dewey TM, Chen JM, Spanier TB, Oz MC (1999). Alternative technique of right-sided outflow cannula insertion for right ventricular support. Ann Thorac Surg, 66(5), 1829-30. (Read full article)
    62. Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, Rose EA, Schmidt AM (1998). Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg, 115(5), 1179-88. (Read full article)
    63. Spanier T, Smith CR, Burkhoff D (1998). Angiogenesis: a possible mechanism underlying the clinical benefits of transmyocardial laser revascularization. J Clin Laser Med Surg, 15(6), 269-73. (Read full article)
    64. Spanier TB, Burkhoff D, Smith CR (1998). Role for holmium:YAG lasers in transmyocardial laser revascularization. J Clin Laser Med Surg, 15(6), 287-91. (Read full article)
    65. Spanier TB, Oz MC, Madigan JD, Rose EA, Stern DM, Nowygrod R, Schmidt AM (1997). Selective anticoagulation with active site blocked factor IXa in synthetic patch vascular repair results in decreased blood loss and operative time. ASAIO J, 43(5), M526-30. (Read full article)
    66. Spanier T, Oz M, Levin H, Weinberg A, Stamatis K, Stern D, Rose E, Schmidt AM (1996). Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg, 112(4), 1090-7. (Read full article)
    67. Spanier TB, Klein RD, Nasraway SA, Rand WM, Rohrer RJ, Freeman RB, Schwaitzberg SD (1995). Multiple organ failure after liver transplantation. Crit Care Med, 23(3), 466-73. (Read full article)
    68. Nasraway SA, Klein RD, Spanier TB, Rohrer RJ, Freeman RB, Rand WM, Benotti PN (1995). Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation. Evidence for early postoperative myocardial depression. Chest, 107(1), 218-24. (Read full article)
    69. Halpain S, Spanier T, McEwen BS (1986). Loss of 3H-corticosterone binding capacity in hippocampal slices maintained in vitro. Brain Res Bull, 16(2), 167-70. (Read full article)

    Review

    1. Baker T, Tabrizian P, Zendejas I, Gamblin TC, Kazimi M, Boudjema K, Geller D, Salem R (2021). Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group. [Review]. HPB (Oxford), 24(7), 1007-1018. (Read full article)

    Case Report

    1. Siddiqi UA, Hibino N, Combs PS, Baker T, Song T, Kim G, Jeevanandam V (2020). A successful heart and liver transplantation requiring intraoperative extracorporeal membrane oxygenation for primary cardiac allograft dysfunction in a patient with Fontan failure. J Card Surg, 35(6), 1357-1359. (Read full article)

    Editorial

    1. Baker TB (2019). Liver Paired Exchange: Ready for Prime Time in North America? Liver Transpl, 25(11), 1609-1610. (Read full article)
    2. Baker TB (2016). Living liver donation, donor safety, and social media: Preparing for a new frontier. Liver Transpl, 23(2), 131-132. (Read full article)
    3. Ladner DP, Baker T (2012). Near-miss events: a vastly missed opportunity. Liver Transpl, 19(5), 467-9. (Read full article)
    4. Baker TB, Abecassis M, Levitsky J (2012). To kidney or not to kidney, when … is the question. Liver Transpl, 18(8), 875-7. (Read full article)

    Letter

    1. Lambdin J, Ryan CE, Alejandro RH, Baker T, Sapisochin G, Hernandez JM, Al-Adra DP (2022). Neoadjuvant Chemotherapy Plus Living Donor Transplantation (LDLT) for Non-Resectable Liver Metastases from Colorectal Cancer (CRC). [Letter to the editor]. Ann Surg Oncol, 30(1), 18-20. (Read full article)
    2. Ebong IA, Sayer G, Kim G, Jeevanandam V, Baker T, Becker Y, Fung J, Charlton M, Te H, Josephson M, Uriel N (2019). Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. [Letter to the editor]. J Heart Lung Transplant, 38(9), 997-999. (Read full article)